Abstract
The ability of allogeneic hematopoietic cell transplantation (HCT) to cure hematologic malignancies is widely recognized. An important therapeutic aspect of HCT in eradicating malignant cells is the graft-versus-leukemia (GVL) effect. But the GVL effect is closely associated with graft-versus-host disease (GVHD) the major complication of HCT. GVHD remains the major barrier to the wider application of allogeneic HCT for a variety of diseases. GVHD occurs in two forms, acute and chronic, and both are associated with GVL effects. Recent advances in the understanding of genetic polymorphisms, the chemo-cytokine networks, several novel cellular subsets including regulatory T cells, and of the direct mediators of cellular cytotoxicity have led to improved understanding of these complex processes. Animal studies show that modulating several mediators of the complex GVHD cascade may be able to reduce the undesirable inflammatory aspects of GVHD while preserving the benefits of GVL. However, most of the laboratory observations remain to be studied in well-controlled clinical trials. Multiple cellular effectors may be involved in GVL, although donor T cell recognition of host antigens is an important element of this process. Cellular immunotherapy such as donor leukocyte infusion offers a strategy for separating GVHD and the GVL effect. Both experimental and clinical data suggest that post-transplantation cellular immunotherapy can be performed relatively safely and effectively, and optimization of patient selection, cell dose, and timing of administration may all serve to limit toxicity and enhance the potential GVL effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barnes D, Corp M, Loutit J, Neal F (1956) Treatment of murine leukaemia with X-rays and homologous bone marrow: preliminary communication. Br Med J 2:626–630
Barnes D, Loutit J (1957) Treatment of murine leukaemia with X-rays and homologous bone marrow. Br J Haematol 3:241–252
Truitt R, Johnson B, McCabe C, Weiler M (1997) Graft versus leukemia. In: Ferrara J, Deeg H, Burakoff S (eds) Graft-vs-host disease (edn 2). Marcel Dekker, Inc., New York, pp 385–424
Billingham RE (1966) The biology of graft-versus-host reactions. Harvey Lec 62:21–78
Petersdorf EW (2006) Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol 18(5):559–564
Erlich HA, Opelz G, Hansen J (2001) HLA DNA typing and transplantation. Immunity 14(4):347–356
Shlomchik WD (2007) Graft-versus-host disease. Nat Rev Immunol 7(5):340–352
Mori M, Beatty PG, Graves M, Boucher KM, Milford EL (1997) HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64(7):1017–1027
Deeg HJ, Cottler-Fox M (1990) Clinical spectrum and pathophysiology of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds) Graft-vs.-host disease: immunology, pathophysiology, and treatment. Marcel Dekker, Inc., New York, pp 539–555
Arai S, Lee LA, Vogelsang GB (2002) A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 11(2):215–229
Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8(3):155–160
Sale GE, Shulman HM (1984) The pathology of bone marrow transplantation. Masson, New York
Sale GE (1996) Does graft-versus-host disease attack epithelial stem cells? Mol Med Today 2:114–119
Sale GE, Shulman HM, Gallucci BB, Thomas ED (1985) Young rete ridge keratinocytes are preferred targets in cutaneous graft-vs-host disease. Am J Pathol 118:278–287
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan NA (2003) Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 9(8):512–518
Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, Lerner K, Thomas E (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18:295–304
Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM, Aker SN, Salazar RC, McDonald GB (2006) An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 108(2):749–755
Martin P, Schoch G, Fisher L, Byers V, Anasetti C, Applebaum F, Beatty P, Doney K, McDonald G, Sanders J, Sullivan K, Storb R, Thomas E, Witherspoon R, Lomen P, Hannigan J, Hansen J (1990) A retrospective analysis of therapy for acute graft-versus-host diesase: initial Treatment. Blood 76:1464–1472
Deeg HJ, Antin JH (2006) The clinical spectrum of acute graft-versus-host disease. Semin Hematol 43(1):24–31
Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12):2964–2968
Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29(3):259–277
Vogelsang GB, Lee L, Bensen-Kennedy DM (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 54:29–52
Ferrara JLM, Deeg HJ (1991) Graft versus host disease. N Engl J Med 324:667–674
Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V, Braine HG, Noga SJ, Vogelsang GB (1999) Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 67(5):681–689
Iqbal N, Salzman D, Lazenby AJ, Wilcox CM (2000) Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol 95(11):3034–3038
Ponec RJ, Hackman RC, McDonald GB (1999) Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 49(5):612–621
Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S, McGlave P (1985) A histopathological study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16:387–392
Cooke KR, Yanik G (2004) Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 34(9):753–765
Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, Maloney DG, Deeg HJ, Martin PJ, Storb RF, Madtes DK (2003) Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102(8):2777–2785
Lee CK, Gingrich RD, Hohl RJ, Ajram KA (1995) Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 16(1):175–182
Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ, Suffredini A, Childs R (2005) Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant 11(7):542–550
Spitzer TR (2001) Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 27(9):893–898
Sviland L, Pearson AD, Eastham EJ, Hamilton PJ, Proctor SJ, Malcolm AJ (1988) Histological features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol 41(2):148–154
Reddy P, Ferrara JL (2003) Immunobiology of acute graft-versus-host disease. Blood Rev 17(4):187–194
Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffman RG, Kay HEM, Kersey JH, Marmont A, Masaoka T, Rimm AA, van Rood JJ, Zwaan FE (1987) Risk factors for acute graft-versus-host disease. Br J Haematol 67:397–406
Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LB, Anasetti C, Beatty P, Bensigner WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76:1867–1871
Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360–2367
Hill G, Ferrara J (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9):2754–2759
Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293(5528):293–297
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204–3213
Matzinger P (2002) The danger model: a renewed sense of self. Science 296(5566):301–305
Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285(5426):412–415
Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, Hamada H, Asakura H, Ishikawa H, Matsushima K (2003) Peyer’s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4(2):154–160
Cooke K, Hill G, Crawford J, Bungard D, Brinson Y, Delmonte J Jr, Ferrara J (1998) Tumor necrosis factor-a production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft versus host disease. J Clin Invest 102:1882–1891
Slavin S (2000) New strategies for bone marrow transplantation. Curr Opin Immunol 12(5):542–551
Velardi A, Ruggeri L, Alessandro Moretta, Moretta L (2002) NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 23(9):438–444
Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL (2002) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8(6):575–581
Jones SC, Murphy GF, Friedman TM, Korngold R (2003) Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest 112(12):1880–1886
Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11(11):1244–1249
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C (2000) Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95(8):2484–2490
Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA (2002) Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 99(4):1442–1448
MacDonald KP, Rowe V, Clouston AD, Welply JK, Kuns RD, Ferrara JL, Thomas R, Hill GR (2005) Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 174(4):1841–1850
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, Ferrara JL, Teshima T (2004) Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172(12):7393–7398
Sato K, Yamashita N, Baba M, Matsuyama T (2003) Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18(3):367–379
Maeda Y, Reddy P, Lowler KP, Liu C, Bishop DK, Ferrara JL (2005) Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood 106(2):749–755
Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M (2006) Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107(9):3787–3794
Macdonald KP, Kuns RD, Rowe V, Morris ES, Banovic T, Bofinger H, O’Sullivan B, Markey KA, Don AL, Thomas R, Hill GR (2007) Effector and regulatory T cell function is differentially regulated by RelB within antigen presenting cells during GVHD. Blood 109:5049–5057
Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG (2007) Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 178(5):2893–2900
Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA, Charo I, Cook DN, Weissman IL, Strober S, Engleman EG (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10(5):510–517
Nachbaur D, Kircher B, Eisendle K, Latzer K, Haun M, Gastl G (2003) Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. Br J Haematol 123(1):119–126
Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, Morris ES, Burman AC, Bofinger HM, Clouston AD, Hill GR (2006) Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 108(7):2485–2492
Korngold R, Sprent J (1980) Negative selection of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers. Role of the H-2 complex. J Exp Med 151(5):1114–1124
Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, Baker EM, Cao YA, Contag CH, Negrin RS (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106(3):1113–1122
Shlomchik WD (2003) Antigen presentation in graft-vs-host disease. Exp Hematol 31(12):1187–1197
Lechler R, Ng WF, Steinman RM (2001) Dendritic cells in transplantation—friend or foe? Immunity 14(4):357–368
Sayegh MH, Carpenter CB (1996) Role of indirect allorecognition in allograft rejection. Int Rev Immunol 13(3):221–229
Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD (2004) Target antigens determine graft-versus-host disease phenotype. J Immunol 173(9):5467–5475
Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ (2005) Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105(5):2227–2234
Appleman LJ, Boussiotis VA (2003) T cell anergy and costimulation. Immunol Rev 192:161–180
Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2(2):116–126
Bromley SK, Iaboni A, Davis SJ, Whitty A, Green JM, Shaw AS, Weiss A, Dustin ML (2001) The immunological synapse and CD28-CD80 interactions. Nat Immunol 2(12):1159–1166
Dustin ML (2001) Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 21(4):258–263
Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548
Welniak LA, Blazar BR, Murphy WJ (2006) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139–170
Blazar BR, Taylor PA, Linsley PS, Vallera DA (1994) In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815–3825
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA (1997) Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 158(1):29–39
Blazar BR, Taylor PA, Panoskaltis-Mortari A, Gray GS, DA V (1995) Co-blockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607–2618
Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA (2001) Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 166(5):3174–3183
Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, Akiba H, Yagita H, Killeen N, Taylor PA (2003) Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101(9):3741–3748
Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, Nishimura H, Taylor PA (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171(3):1272–1277
Csencsits KL, Bishop DK (2003) Contrasting alloreactive CD4+ and CD8+ T cells: there’s more to it than MHC restriction. Am J Transplant 3(2):107–115
Korngold R, Sprent J (1982) Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med 155(3):872–883
Korngold R, Sprent J (1985) Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. Journal of Immunology 135:3004–3010
Korngold R, Sprent J (1987) T cell subsets and graft-versus-host disease. Transplantation 44(3):335–339
Wu CJ, Ritz J (2006) Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 90:133–173
Goulmy E (2006) Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 67(6):433–438
Spierings E, Drabbels J, Hendriks M, Pool J, Spruyt-Gerritse M, Claas F, Goulmy E (2006) A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE 1:e42
Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, Shlomchik WD (2003) Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 112(1):101–108
Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ (2004) Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 103(4):1534–1541
Zhang Y, Joe G, Zhu J, Carroll R, Levine B, Hexner E, June C, Emerson SG (2004) Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 103(10):3970–3978
Maeda Y, Tawara I, Teshima T, Liu C, Hashimoto D, Matsuoka K, Tanimoto M, Reddy P (2007) Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Exp Hematol 35(2):274–286
Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG (2005) Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol 174(5):3051–3058
Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG (2005) Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 11(12):1299–1305
Blazar BR, Taylor PA (2005) Regulatory T cells. Biol Blood Marrow Transplant 11(Suppl 2):46–49
Cohen JL, Boyer O (2006) The role of CD4(+)CD25(hi) regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 18:580–585
Johnson BD, Konkol MC, Truitt RL (2002) CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 8(10):525–535
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196(3):389–399
Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL (2002) CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 196(3):401–406
Roncarolo MG (1997) The role of interleukin-10 in transplantation and GVHD. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds) Graft-vs.-host disease. Marcel Dekker, Inc., New York, pp 693–715
Young KJ, DuTemple B, Phillips MJ, Zhang L (2003) Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 171(1):134–141
Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S (1999) Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189(7):1073–1081
Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353(13):1321–1331
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144–1150
Nguyen VH, Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, Negrin RS (2007) In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 109(6):2649–2656
Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV (2003) CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk of graft-versus-host disease following HLA-identical stem cell transplantation in humans. Blood 103:1140–1146
Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD (2004) Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104(7):2187–2193
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J (2005) Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106(8):2903–2911
Ziegler SF (2006) FOXP3: of mice and men. Annu Rev Immunol 24:209–226
Hashimoto D, Asakura S, Miyake S, Yamamura T, Van Kaer L, Tanimoto M, Teshima T (2003) Host NKT cells promote Th2 polarization of donor T cells and regulate acute GVHD after experimental BMT via a STAT6-dependent mechanism. Blood 102(Suppl 11):191a
Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger HM, Burman AC, Olver SD, Kienzle N, Porcelli SA, Pellicci DG, Godfrey DI, Smyth MJ, Hill GR (2005) NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115(11):3093–3103
Morris ES, MacDonald KP, Hill GR (2006) Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 107(9):3430–3435
Wang JW, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, Nguyen KH, Toyama-Sorimachi N, Kerr WG (2002) Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295(5562):2094–2097
Kamradt T, Mitchison NA (2001) Tolerance and autoimmunity. N Engl J Med 344(9):655–664
Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S, Shaffer J, Turka L, Sykes M (2001) Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 166(4):2311–2316
Sykes M, Sachs DH (2001) Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 356(1409):707–726
Li XC, Strom TB, Turka LA, Wells AD (2001) T cell death and transplantation tolerance. Immunity 14(4):407–416
Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA (2001) Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166(2):973–981
Van Parijs L, Ibraghimov A, Abbas AK (1996) The roles of costimulation and Fas in T-cell apoptosis and peripheral tolerance. Immunity 4:321–328
Sykes M, Abraham VS (1992) The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells. Transplantation 53:1063–1070
Sykes M, Abraham VS, Harty MW, Pearson DA (1993) IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150:197–205
Yang Y, Dey B, Sergio J, Sykes M (1997) Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model. Transplantation 64:1343–1352
Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M (1998) Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 102(12):2126–2135
Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K, Ferrara JL (2001) Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 194(10):1433–1440
Marrack P, Mitchell T, Bender J, Hildeman D, Kedl R, Teague K, Kappler J (1998) T-cell survival. Immunol Rev 165:279–285
Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P (2002) Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16(6):759–767
Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P (2002) Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 14(3):354–359
Drobyski WR, Komorowski R, Logan B, Gendelman M (2002) Role of the passive apoptotic pathway in graft-versus-host disease. J Immunol 169(3):1626–1633
Drobyski WR, Gendelman M (2002) Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. Leuk Lymphoma 43(10):2011–2016
Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA (2002) Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99(3):806–814
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276(5319):1719–1724
Chen BJ, Cui X, Liu C, Chao NJ (2002) Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99(9):3083–3088
Ferrara J, Krenger W (1998) Graft Versus Host Disease: the Influence of Type 1 and Type 2 T Cell Cytokines. Transfus Med Rev 12:1–17
Ferrara JLM (1994) The cytokine storm of acute graft-versus host disease. Haematol Rev 8:27
Reddy P (2003) Pathophysiology of acute graft-versus-host disease. Hematol Oncol 21(4):149–161
Ratanatharathorn V, Nash RA, Przepiorka D et al (1998) Phase III study comparing methotrexate and tacrolimus (prpgraf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303–2314
Liu EH, Siegel RM, Harlan DM, O’Shea JJ (2007) T cell-directed therapies: lessons learned and future prospects. Nat Immunol 8(1):25–30
Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108(1):390–399
Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11(11):1238–1243
Liston A, Rudensky AY (2007) Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol 19(2):176–185
Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445(7129):771–775
Yang Y-G, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M (1997) Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood 90:4651–4660
Sykes M, Pearson DA, Taylor PA, Szot GL, Goldman SJ, Blazar BR (1999) Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol Blood Marrow Transplant 5(5):277–284. doi:S1083-8791(99)70002-9
Reddy P (2004) Interleukin-18: recent advances. Curr Opin Hematol 11(6):405–410
Sykes M, Harty MW, Szot GL, Pearson DA (1994) Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83:2560–2569
Sykes M, Szot GL, Nguyen PL, Pearson DA (1995) Interleukin-12 inhibits murine graft-versus-host disease. Blood 86:2429–2438
Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE (1994) Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540
Krenger W, Snyder KM, Byon CH, Falzarano G, Ferrara JLM (1995) Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585–593
Pan L, Delmonte J, Jalonen C, Ferrara J (1995) Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422–4429
Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, Bungard D, Ferrara JL (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102(1):115–123
Reddy P, Teshima T, Hildebrandt G, Williams DL, Liu C, Cooke KR, Ferrara JL (2003) Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 101(7):2877–2885
Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, Bierer BE, Fowler DH (2005) Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 175(9):5732–5743
Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH (2006) Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin herapy. Biol Blood Marrow Transplant 12(9):905–918
Fowler DH, Gress RE (2000) Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 38(3–4):221–234
Nikolic B, Lee S, Bronson R, Grusby M, Sykes M (2000) Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 105:1289–1298
Blazar BR, Taylor PA, Smith S, Vallera DA (1995) Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 85:842–851
Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA (2003) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349(23):2201–2210
Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, Kelly J, Ledbetter S, Clouston AD, Hill GR (2005) TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 106(6):2206–2214
Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MR (2001) Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98(7):2256–2265
Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Greenberg AS, Kappel BJ, van den Brink MR (2003) IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest 112(7):1095–1107
Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL (2002) Interleukin 7 worsens graft-versus-host disease. Blood 100(7):2642–2649
Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski WR (2004) Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J Immunol 172(5):3328–3336
Weaver CT, Murphy KM (2007) T-cell subsets: the more the merrier. Curr Biol 17(2):R61–63
Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS (2005) Leukocyte migration and graft-versus-host disease. Blood 105(11):4191–4199
Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127–159
Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR (2000) T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 96(9):2973–2980
Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A, Sykes M (2006) Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant 12(6):623–634
Duffner U, Lu B, Hildebrandt GC, Teshima T, Williams DL, Reddy P, Ordemann R, Clouthier SG, Lowler K, Liu C, Gerard C, Cooke KR, Ferrara JL (2003) Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 31(10):897–902
Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, Blazar BR, Serody JS (2004) Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol 173(2):845–854
Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, Suzuki K, Asakura H, Matsushima K (1999) Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 104(1):49–57
Wysocki C, Burkett S, Chwastiak K, Taylor P, Blazar BR, Serody JS (2003) CCR5 expression on CD4+CD25+ regulatory T cells plays a critical role in their ability to prevent GVHD. Blood 102(11):517
Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR (2006) Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 107(4):1703–1711
Welniak LA, Kuprash DV, Tumanov AV, Panoskaltsis-Mortari A, Blazar BR, Sun K, Nedospasov SA, Murphy WJ (2005) Peyer’s patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. Blood 107:410–412
Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M (2003) Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 111(5):659–669
Lee RS, Kuhr CS, Sale GE, Zellmer E, Hogan WJ, Storb R, Little MT (2003) FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model. Transplantation 76(8):1155–1158
Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18:593–620
Sackstein R (2006) A revision of Billingham’s tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 12(Suppl 1):2–8
Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528–530
van den Brink MR, Burakoff SJ (2002) Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2(4):273–281
Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R (1997) The receptor for the cytotoxic ligand TRAIL. Science 276(5309):111–113
Chicheportiche Y, Bourdon P, Xu H, Hsu Y, Scott H, Hession C, Garcia I, Browning J (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272:32401–34210
Jiang S, Herrera O, Lechler RI (2004) New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 16(5):550–557
Jiang Z, Podack E, Levy R (1998) Donor T cells which cannot mediate perforin-dependent and FasL-dependent cytotoxicity can effect graft vs host reactivity following allogeneic bone marrow transplantation. Periodicum Biologorum 100:477–481
Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, Ferrara JL (2005) Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 105(5):2023–2027
Voskoboinik I, Smyth MJ, Trapani JA (2006) Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6(12):940–952
Chinnaiyan A, O’Rourke K, Yu G, Lyons R, Garg M, Duan D, Xing L, Gentz R, Ni J, Dixit V (1996) Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274:990–992
Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407(6805):789–795
Baker MB, Altman NH, Podack ER, Levy RB (1996) The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645–2656
Braun YM, Lowin B, French L, Acha-Orbea H, Tschopp J (1996) Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657–661
Baker MB, Riley RL, Podack ER, Levy RB (1997) GVHD-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A 94:1366–1371
Graubert TA, Russell JH, Ley T (1996) The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 87:1232–1237
Graubert TA, DiPersio JF, Russell JH, Ley TJ (1997) Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100(4):904–911
Ueno Y, Ishii M, Yahagi K, Mano Y, Kisara N, Nakamura N, Shimosegawa T, Toyota T, Nagata S (2000) Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 31(4):966–974
Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745–756
Via C, Nguyen P, Shustov A, Drappa J, Elkon K (1996) A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157:5387–5393
Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91(11):4051–4055
van den Brink M, Moore E, Horndasch E, Crawford J, Hoffman J, Murphy G, Burakoff S (2000) Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 164:469–480
Lin T, Brunner T, Tietz B, Madsen J, Bonfoco E, Reaves M, Huflejt M, Green DR (1998) Fas ligand-mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J Clin Invest 101(3):570–577
Liem LM, van Lopik T, van Nieuwenhuijze AEM, van Houwelingen HC, Aarden L, Goulmy E (1998) Soluble fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 91:1464–1468
Das H, Imoto S, Murayama T, Kajimoto K, Sugimoto T, Isobe T, Nakagawa T, Nishimura R, Koizumi T (1999) Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol 104(4):795–800
Martin PJ, Akatsuka Y, Hahne M, Sale G (1998) Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 92(6):2177–2181
Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB (2005) Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Biol Blood Marrow Transplant 11(8):576–586
Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, Van Den Brink MR (2002) T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8(12):1433–1437
Sato K, Nakaoka T, Yamashita N, Yagita H, Kawasaki H, Morimoto C, Baba M, Matsuyama T (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174(7):4025–4033
Brown GR, Lee E, Thiele DL (2002) TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J–>C57BL/6J x bm12)F1 mice. J Immunol 168(6):3065–3071
Brown GR, Thiele DL (2000) Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions. Eur J Immunol 30(10):2900–2907
Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C (2005) IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 174(8):4688–4695
Xu Y, Flies AS, Flies DB, Zhu G, Anand S, Flies SJ, Xu H, Anders RA, Hancock WW, Chen L, Tamada K (2006) Selective targeting of the LIGHT-HVEM co-stimulatory system for the treatment of graft-versus-host disease. Blood 109:4097–4104
Zimmerman Z, Jones M, Shatry A, Komatsu M, Mammolenti M, Levy R (2005) Cytolytic pathways used by effector cells derived from recipient naive and memory T cells and natural killer cells in resistance to allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11(12):957–971
Ferrara JL, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5(6):347–356
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987–995
Hill GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9):2754–2759
Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7(12):1250–1257
Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 127(5):479–490
Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin MT, Chien JW, Hansen JA, Clark JG (2001) Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7(7):384–387
Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H, Dickinson AM, Socie G, Wolff D, Fischer G, Jackson G, Rocha V, Steiner B, Eissner G, Marienhagen J, Schoelmerich J, Andreesen R (2006) Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107(10):4189–4193
Nestel FP, Price KS, Seemayer TA, Lapp WS (1992) Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175(2):405–413
Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL (1999) Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104(4):459–467
Krenger W, Falzarano G, Delmonte J, Snyder KM, Byon JCH, Ferrara JLM (1996) Interferon-g suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 88:1113–1121
Piguet PF, Grau GE, Allet B, Vassalli PJ (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280–1289
Hill GR, Teshima T, Rebel VI, Krijanovski OI, Cooke KR, Brinson YS, Ferrara JL (2000) The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 164(2):656–663
Piguet PF (1990) Tumor necrosis factor and graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K (eds) Graft-vs.-host disease. Marcel Dekker Inc., New York, pp 255–276
Tanaka J, Imamura M, Kasai M, Masauzi N, Watanabe M, Matsuura A, Morii K, Kiyama Y, Naohara T, Higa T, Honke K, Gasa S, Sakurada K, Miyazaki T (1993) Rapid analysis of tumor necrosis factor-alpha mRNA expression during venooclusive disease of the liver after allogeneic bone marrow transplantation. Transplantation 55:430–432
Tanaka J, Imamura M, Kasai M, Masauzi N, Matsuura A, Ohizumi H, Morii K, Kiyama Y, Naohara T, Saitho M et al (1993) Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 85:558–565
Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermuller J, Wilmanns W (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011–1016
Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelde S, Kaul M, Wilmanns W (1993) The role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25:1234–1236
Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, Lioure B, Roche C, Vilmer E, Demeocq F, Kuentz M, Cahn YJ (1992) Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 81:1993–1999
Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JL, Levine JE (2005) Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-vs.-host disease. Biol Blood Marrow Transplant 11(9):680–687
Antin JH, Ferrara JLM (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964–2968
Abhyankar S, Gilliland DG, Ferrara JLM (1993) Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 56:1518–1523
McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM (1991) Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915–1918
Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100(10):3479–3482
Falzarano G, Krenger W, Snyder KM, Delmonte J, Karandikar M, Ferrara JLM (1996) Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-a in mice with acute graft-versus-host disease. Blood 87:2853–2860
Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS (2000) Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood 96(5):1836–1843
Weiss G, Schwaighofer H, Herold M, Nachbaur D, Wachter H, Niederwieser D, Werner ER (1995) Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 60(11):1239–1244
Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, Simmons RL, Hoffmann RA (1992) Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 90:679–683
Langrehr JM, Muller AR, Bergonia HA, Jacob TD, Lee TK, Schraut WH, Lancaster JR, Hoffman RA, Simmons RL (1992) Detection of nitric oxide by electron paramagnetic resonance spectroscopy during rejection and graft-versus-host disease after small-bowel transplantation in the rat. Surgery 112:395–401
Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2(10):907–916
Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O’Reilly RJ (1986) Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68(3):770–773
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339(17):1186–1193
Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J et al (1990) Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76(2):418–423
Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O’Reilly RJ, Young JW (1998) T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 91(3):1083–1090
Wagner J, Santos G, Noga S (1990) Bone marrow graft engineering by counterflow centrifugal elutration: results of a phase I-II clinical trial. Blood 75(6):1370–1377
Martin PJ, Schoch G, Fisher L et al (1991) A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77:1821–1828
Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, Ramsay M, McGlave P, Filipovich A, Weisdorf D (2000) A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 6(4A):441–447
Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84(4):1320–1327
Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R et al (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84(4):1320–1327
Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95(1):83–89
Carpenter PA, Appelbaum FR, Corey L et al (2002) A humanized non FcR-biding anti-CD3 antibody, visilizumb, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712–2719
Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C (2005) A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 11(6):465–471
Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG (2001) Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 112(3):820–823
Storb R, Epstein RB, Graham TC, Thomas ED (1970) Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9(3):240–246
Ramsay NK, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W, Kim TH, Goldman AI, Nesbit ME Jr (1982) A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306(7):392–397
Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman SJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL (1980) Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302(19):1041–1046
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7):2303–2314
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729–735
Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R et al (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73(6):1729–1734
Chao NJ, Snyder DS, Jain M et al (2000) Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 6:254–261
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA (1998) Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with te production of Th1 or Th1 cytotoxic cytokines. J Immunol 160:5355–5365
Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2–3):85–118
van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D (1974) Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Nat Cancer Inst 52(2):401–404
Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, Singer J, Sullivan KM, Witherspoon RP, Thomas ED (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings Beneficial effect of a protective environment. N Engl J Med 308:302–307
Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller K-D, Quabeck K, Sayer HG, Graeven U, Mahmoud HK, Schaefer UW (1992) Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80:2668–2676
Beelen D, Elmaagacli A, Muller K, Hirche H, Schaefer U (1999) Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long term follow-up of an open-label prospective randomized trial. Blood 93:3267–3275
Passweg J, Rowlings P, Atkinson K et al (1998) Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Tansplant 21:1231–1238
Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83(8):2360–2367
Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL (2001) Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant 28(12):1105–1109
Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, Arai S, Anders V, Vogelsang GB (2002) Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 100(12):3903–3907
Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75(4):1011–1016
Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M, Wilmanns W (1993) Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25(1 Pt 2):1234–1236
Holler E, Kolb HJ, Wilmanns W (1993) Treatment of GVHD–TNF-antibodies and related antagonists. Bone Marrow Transplant 12(Suppl 3):S29–31
Huang XJ, Wan J, Lu DP (2001) Serum TNFalpha levels in patients with acute graft-versus-host disease after bone marrow transplantation. Leukemia 15(7):1089–1091
Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hunerliturkoglu A, Haas R (2001) Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 28(1):47–49
Couriel DR, Hicks K, Giralt S, Champlin RE (2000) Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 12(6):582–587
Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP (2002) Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73(4):665–667
Abhyankar S, Gilliland DG, Ferrara JL (1993) Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56(6):1518–1523
Cullup H, Dickinson A, Jackson G, Taylor P, Cavet J, Middleton P (2000) Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 113:807–813
McCarthy PL, Williams L, Harris-Bacile M, Yen J, Przepiorka D, Ippoliti C, Champlin R, Fay J, Blosch C, Jacobs C, Anasetti C (1996) A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation 62:626–631
Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, Bloedow DC, Abate L, Lebsack M, Burakoff SJ, Ferrara JLM (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84:1342–1348
Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, Ferrara JL (2002) A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29(5):373–377
Martin PJ, Schoch G, Fisher L et al (1991) A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77:1821–1828
Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A (1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75(4):1024–1030
Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB (2007) A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109(10):4557–4563
Deeg HJ (2007) How I treat refractory acute GVHD. Blood 109:4119–4126
Greinix HT, Socie G, Bacigalupo A, Holler E, Edinger MG, Apperley JF, Schwarz T, Ullrich SE, Albert ML, Knobler RM, Peritt D, Ferrara JL (2006) Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 38(4):265–273
Ely P, Dunitz J, Rogosheske J, Weisdorf D (1991) Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 90(6):707–710
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28(3):250–259
Vogelsang GB, Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27(12):1255–1262
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, Storb R, Appelbaum FR, Forman SJ, Blume KG, Martin PJ (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100(2):415–419
Akpek G, Chinratanalab W, Lee LA, Torbenson M, Hallick JP, Anders V, Vogelsang GB (2003) Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 9(1):46–51
Ghayur T, Seemayer T, Lapp WS (1990) Histologic correlates of immune functional deficits in graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds) Graft-vs.-host disease: immunology, pathophysiology, and treatment. Marcel Dekker, New York, pp 109132
Arai S, Vogelsang GB (2000) Management of graft-versus-host disease. Blood Rev 14(4):190–204
Wingard JR, Piantadosi S, Vogelsgang GB, Farmer ER, Jabs DA, Levin LS, Beschorner WE, Cahill RA, Miller DF, Harrison D, Saral R, Santos GW (1989) Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428–1435
Wingard JR, Vogelsang GB, Deeg HJ (2002) Stem cell transplantation: supportive care and long-term complications. Hematology (Am Soc Hematol Educ Program):422-444
Ghayur T, Seemayer T, Lapp WS et al (1990) Histologic correlates of immune functional deficits in graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds) Graft-vs.-host disease: immunology, pathophysiology, and treatment. Marcel Dekker, New York, pp 109–132
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956
Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ (2006) National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report. Biol Blood Marrow Transplant 12(5):491–505
Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2001) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 28(2):121–129
Reddy P, Johnson K, Uberti JP, Reynolds C, Silver S, Ayash L, Braun TM, Ratanatharathorn V (2006) Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 38(5):351–357
Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, Vogelsang GB (2001) Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97(5):1219–1226
Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB (1988) A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8(3):463–470
Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K, Gallucci B, Thomas ED, Storb R (1978) Chronic cutaneous graft-versus-host disease in man. Am J Pathol 91(3):545–570
Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ (2007) Transplantation’s greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 13(Suppl 1):2–10
Parkman R (1993) Is chronic graft versus host disease an autoimmune disease? Curr Opin Immunol 5(5):800–803
Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, Tanimoto M, Teshima T (2007) Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109(4):1756–1764
Hess AD, Horwitz L, Beschorner WE, Santos GW (1985) Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 161(4):718–730
Hess A, Thoburn C, Bright E, Horwitz L (1997) Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide (CLIP). Transplant Proc 29(1–2):725–727
Holländer GA, Widmer B, Burakoff SJ (1994) Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs. host disease. J Immunol 152:1609–1617
Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL (2003) Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 102(2):429–435
Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP (2003) Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9(8):505–511
Cutler C, Antin JH (2006) Chronic graft-versus-host disease. Curr Opin Oncol 18(2):126–131
Lee SJ (2005) New approaches for preventing and treating chronic graft-versus-host disease. Blood 105(11):4200–4206
Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, Appelbaum FR, Carpenter PA, Sanders JE, Kiem HP, Nash RA, Petersdorf EW, Moravec C, Morton AJ, Anasetti C, Flowers ME, Martin PJ (2004) Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104(12):3501–3506
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102(2):756–762
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, MittelmanB, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME (2006) Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 12(4):375–396
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM (2002) Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100(2):406–414
Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR et al (1988) Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72(2):546–554
Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C et al (1988) Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72(2):555–561
Investigator’s Brochure (1997) Recombinant human keratinocyte growth (r-HuKGF), 3.0 ed. Amgen, Inc.
Hess AD (1997) The immunobiology of syngeneic/autologous graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds) Graft-vs.-host disease. Marcel Dekker, Inc., New York, pp 561–586
Ichinohe T, Teshima T, Matsuoka K, Maruya E, Saji H (2005) Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation. Curr Opin Immunol 17(5):546–552
Anderson KC, Weinstein HJ (1990) Transfusion-associated graft-versus-host disease. N Engl J Med 323:315–321
Orlin JB, Ellis MH (1997) Transfusion-associated graft-versus-host disease. Curr Opin Hematol 4(6):442–448
Schroeder ML (2002) Transfusion-associated graft-versus-host disease. Br J Haematol 117(2):275–287
Bortin MM, Rimm AA, Saltzstein E (1973) Graft-versus-leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 173:811–813
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300(19):1068–1073
Gale RP, Champlin RE (1984) How does bone-marrow transplantation cure leukaemia? Lancet 2(8393):28–30
Gale RP, Butturini A (1994) Stem cells, clonality and leukemia. Gematol Transfuziol 39(6):3–6
Horowitz MM, Bortin MM (1990) Current status of allogeneic bone marrow transplantation. Clin Transplant 4(2):41–52
Gale R, Horowitz M, Ash R (1994) Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646–652
Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369–386
Collins R, Rogers Z, Bennett M et al (1992) Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391–395
Higano C, Brixey M, Bryant E et al (1990) Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation: a case report of a probable graft-versus-leukemia effect. Transplantation 50:175–177
Sullivan K, Storb R, Buckner D, Fefer A (1989) Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828–834
Odom L, August C, Githens J (1978) Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia” reaction in man? Lancet 2:537–540
Weiden P, Flournoy N, Donnall Thomas E et al (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–1073
Sullivan K, Weiden P, Storb R (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728
Weiden P, Sullivan K, Flournoy N et al (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–1533
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555–562
Weiden PL, Zuckerman N, Hansen JA, Sale GE, Remlinger K, Beck TM, Buckner CD (1981) Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusion. Blood 57(2):328–332
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB et al (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 108(6):806–814
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read E, Tisdale J, Dunbar C, Linehan W, Neal S, Barrett A (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic periphereal-blood stem-cell transplantation. N Engl J Med 343:750–758
Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E et al (1991) Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78(8):2139–2149
Martin PJ, Hansen JA, Storb R, Thomas ED (1985) T cell depletion of donor marrow for prevention of acute graft-versus-host disease. Haematol Blood Transfus 29:42–43
Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J et al (1986) Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105(1):20–26
Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R et al (1992) Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10(7):1191–1200
Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, Weshler Z, Samuel S, Manor D, Brautbar C et al (1984) Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2(8401):483–486
Wagner JE, Santos GW, Noga SJ, Rowley SD, Davis J, Vogelsang GB, Farmer ER, Zehnbauer BA, Saral R, Donnenberg AD (1990) Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I–II clinical trial. Blood 75(6):1370–1377
Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH, Gulati SC, Brochstein JA, Heller G, Black P et al (1992) T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 79(12):3380–3387
Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AW, Gordon-Smith EC et al (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1(1):53–66
Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314(4):202–207
Ho VT, Soiffer RJ (2002) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192–3204
Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA (2003) New directions in natural killer cell-based immunotherapy of human cancer. Expert Opin Biol Ther 3(2):237–250
Bleakley M, Riddell SR (2004) Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4(5):371–380
Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117(5):1137–1146
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475–482
Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117(5):1195–1203
Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411(6835):385–389
Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C (2001) Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 7(7):789–794
Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, Bornhauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, van Rood JJ, Petersdorf E (2006) KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12(8):828–836
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100
Petersdorf EW, Malkki M (2006) Genetics of risk factors for graft-versus-host disease. Semin Hematol 43(1):11–23
Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105(12):4878–4884
Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM (2006) The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12(8):876–884
Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ (2007) Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109:5058–5061
Ferrara JL, Reddy P (2006) Pathophysiology of graft-versus-host disease. Semin Hematol 43(1):3–10
Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R (2004) Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy—from bench to patient bedside. Semin Oncol 31(1):4–21
Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100(5):1903–1909
Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22(6):1136–1151
Chakraverty R, Cote D, Buchli J, Cotter P, Hsu R, Zhao G, Sachs T, Pitsillides CM, Bronson R, Means T, Lin C, Sykes M (2006) An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 203(8):2021–2031
Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115(6):1616–1626
Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907–912
Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP (2007) Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 117(2):492–501
Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M (2006) Host MHC Class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108:2106–2113
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148
Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E (1997) The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-Cell line with potent in vivo graft-versus-leukemia properties. Blood 89(9):3477–3485
Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103(3):767–776
Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA (1997) CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 159(7):3460–3473
Blazar B, Taylor P, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell R, Korngold R, Noelle R, Vallera D (1997) Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunology 158:29–39
Porter DL, Antin JH (2006) Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol 19(4):737–755
Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D (1996) Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukemia cells processing and presenting exogenous antigen. Br J Haematol 93:606–612
Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, Weisdorf D, McGlave P (2001) Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98(10):2922–2929
Dodi IA, Van Rhee F, Forde HC, Roura-Mir C, Jaraquemada D, Goldman JM, Madrigal JA (2002) CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy 4(4):353–363
Madrigal JA, Travers PJ, Dodi IA (2005) Immunotherapeutic aspects of stem cell transplantation. Hematology 10(Suppl 1):289–292
Jones SC, Murphy GF, Korngold R (2003) Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 9(4):243–256
Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MR (2003) Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101(6):2440–2445
Korngold R, Marini JC, De Baca ME, Murphy GF, Giles-Komar J (2003) Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 9(5):292–303
Hsieh MH, Korngold R (2000) Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 96(3):1047–1055
Hsieh MH, Patterson AE, Korngold R (2000) T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. Biol Blood Marrow Transplant 6(3):231–240
Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11(1):77–84
Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11(1):71–76
Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101(11):3921–3926
Porter D, Connors J, Van Deerlin V, Duffy K, McGarigle C, Saidman S, Leonard D, Antin J (1999) Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 17(4):1234–1243
van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377–3383
Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050
Kolb H, Mittermuller J, Clemm C et al (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenousleukemia in marrow transplant patients. Blood 76:2462–2465
Porter D, Roth M, McGarigle C et al (1994) Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106
Drobyski W, Keever C, Roth M, Koeth S, Hanson G, McFadden P, Gottschall J, Ash RC, van Tuinen P, Horowitz MM (1993) Salvage immunotherapy using donor leukocyte transfusions as treatment for relapse chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310–2318
Hertenstein B, Wiesneth M, Novotny J et al (1993) Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114
Collins RH, Shpilberg WR, Drobyski WR, Porter DL, Giralt S (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15(2):433–444
Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E, Cwynarski K, Olavarria E, Yong A, Apperley JF, Goldman JM (2000) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96(8):2712–2716
Dazzi F, Szydlo RM, Apperley JF, Goldman JM (2002) Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood 100(7):2673–2674
Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 26(5):511–516
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5):2041–2050
Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J (1999) Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 32(5–6):505–512
Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20(2):405–412
Kolb HJ, Schmid C, Weisser M, Pihusch M, Tischer J, Pihusch R, Stoetzer O, Ledderose G, Schleuning M (2002) Cytoreduction, DLI, or mobilized peripheral blood progenitors. Ann Hematol 81(Suppl 2):S30–33
Slavin S, Morecki S, Weiss L, Or R (2002) Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 11(2):265–276
Ruggeri L, Capanni M, Martelli MF, Velardi A (2001) Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol 8(6):355–359
Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R (1996) Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18(3):669–672
Mandigers CM, Meijerink JP, Raemaekers JM, Schattenberg AV, Mensink EJ (1998) Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet 352(9139):1522–1523
Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett AJ, Horowitz M, Collins RH (2000) Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 26(11):1179–1184
Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, Donk NW, Verdonck LF (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18(16):3031–3037
Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O’Reilly RJ (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–1191
Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549–1555
Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE (2001) Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol 258:221–229
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241
Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99(11):3916–3922
Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101(2):407–414
Frassoni F, Fagiloli F, Sessarego M et al (1992) The affect of donor leukocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp Hematol 20:712
Flowers ME, Kansu E, Sullivan KM (1999) Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin N Am 13(5):1091–1112, viii–ix
Elfenbein G, Graham-Pole J, Weiner R, Goedert T, Gross S (1987) Consequences of no prophylaxis for acute graft-versus-host disease after HLA-identical bone marrow transplantation (abstract). Blood 70(Suppl 1):305a
Sullivan K, Schulman H (1989) Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. Transplant Proc 21:51–62
Porter D, Antin J (1997) Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In: Winter J (ed) Blood stem cell transplantation. Kluwer Academic Publishers, Norwell, pp 57–86
Porter D, Roth M, McGarigle C et al (1994) Induction of graft-vs-leukemia (GVL) reaction as therapy for relapsed leukemia after allogeneic bone marrow transplantation (BMT). J Cell Biochem 18B:94a
Nash A, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon R (1992) Acute graft-versus-host disease analysis of risk factors after allogeneic marrow transpantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838–1845
Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V (2003) Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 9(3):189–197
Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108–3114
Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91(10):3671–3680
Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME, Maloney DG, Chauncey T, Bruno B, Agura E, Forman SJ, Blume KG, Niederwieser D, Storb R, Sandmaier BM (2004) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103(3):790–795
Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR (2001) Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 7(11):604–612
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science + Bussines Media, LLC
About this chapter
Cite this chapter
Ferrara, J.L.M., Reddy, P. (2012). Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. In: Baharvand, H., Aghdami, N. (eds) Advances in Stem Cell Research. Stem Cell Biology and Regenerative Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-940-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-61779-940-2_16
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-939-6
Online ISBN: 978-1-61779-940-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)